0QF:F:F-Moderna Inc (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 63

Change

-1.80 (-2.78)%

Market Cap

USD 24.99B

Volume

347.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Address: 200 Technology Square, Cambridge, MA, United States, 02139

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOVA:F Novo Nordisk A/S

-0.50 (-0.42%)

USD 547.87B
NOV:F Novo Nordisk A/S

-1.44 (-1.20%)

USD 547.87B
RGO:F Regeneron Pharmaceuticals Inc

-1.50 (-0.15%)

USD 114.77B
CSJ:F CSL Limited

-1.18 (-0.66%)

USD 88.37B
CSJA:F CSL LTD SPON.ADR 2

-0.50 (-0.56%)

USD 87.08B
UNC0:F UCB S.A. UNSP.ADR 1/2

-3.00 (-3.68%)

USD 30.35B
DUL:F Alnylam Pharmaceuticals Inc

+4.20 (+1.74%)

USD 30.08B
1AEA:F argenx SE

-14.00 (-2.93%)

USD 29.03B
1AE:F Argen-X

-14.70 (-3.05%)

USD 28.94B
22UA:F BioNTech SE

-7.60 (-6.75%)

USD 26.15B

ETFs Containing 0QF:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -29.54% 36% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.54% 36% F 17% F
Trailing 12 Months  
Capital Gain -40.28% 34% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.28% 34% F 15% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -3.28% 57% F 36% F
Dividend Return -3.28% 56% F 32% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 56.62% 23% F 18% F
Risk Adjusted Return -5.80% 61% D- 37% F
Market Capitalization 24.99B 98% N/A 93% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector